Effective communication of antimicrobial susceptibility data by pathologists to clinicians

Advances in Experimental Medicine and Biology

Volumn 563, Issue , 2005, Pages 165-177

  Waites, Ken B ^a,b  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFALOTIN; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; METICILLIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; COST EFFECTIVENESS ANALYSIS; GRAM NEGATIVE INFECTION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL INFECTION; HUMAN; INTERPERSONAL COMMUNICATION; LABORATORY TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROORGANISM DETECTION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; REVIEW; STAPHYLOCOCCUS INFECTION; HOSPITAL INFORMATION SYSTEM; INFECTION CONTROL; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PATHOLOGY; PUBLIC RELATIONS; STANDARD;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA;

CLINICAL LABORATORY INFORMATION SYSTEMS; DISEASE NOTIFICATION; DRUG RESISTANCE, MICROBIAL; HUMANS; INTERPROFESSIONAL RELATIONS; MICROBIAL SENSITIVITY TESTS; MICROBIOLOGY; PATHOLOGY, CLINICAL;

EID: 33644843107     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-32025-3_15     Document Type: Review

References (18)

1. Anonymous. Performance Standards for Antimicrobial Susceptibility Testing; Fourteenth Informational Supplement, NCCLS Document M100-S-14, vol. 23. Wayne, PA: National Committee for Clinical Laboratory Standards, 2004.
2. Schentag JJ, Ballow CH, Fritz AL, et al., Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diagn Microbiol Infect Dis, 16(3), 255-64 (1993).
3. Hardy DJ, Hulbert BB, Migneault PC, Time to detection of positive BacT/Alert blood cultures and lack of need for routine subculture of 5- to 7-day negative cultures. J Clin Microbiol, 30(10), 2743-5 (1992).
4. Wilson ML, Introduction. Clinics in Laboratory Medicine, 14(1-7 (1994).
5. Arbique J, Forward K, Haldane D, Davidson R, Comparison of the Velogene Rapid MRSA Identification Assay, Denka MRSA-Screen Assay, and BBL Crystal MRSA ID System for rapid identification of methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis, 40(1-2), 5-10 (2001).
6. Carbon C, Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci. J Antimicrob Chemother, 44 Suppl A(31-6 (1999).
7. Siberry GK, Tekle T, Carroll K, Dick J, Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis, 37(9), 1257-60 (2003).
8. Naimi TS, LeDell KH, Como-Sabetti K, et al., Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. Jama, 290(22), 2976-84 (2003).
9. Appleman MD, Citron DM, Kwok R, Evaluation of the Velogene genomic assay for detection of vanA and vanB genes in vancomycin-resistant Enterococcus species. J Clin Microbiol, 42(4), 1751-2 (2004).
10. Anonymous, Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. MMWR Morb Mortal Wkly Rep, 46(33), 765-6 (1997).
11. Chavers LS, Moser SA, Benjamin WH, et al., Vancomycin-resistant enterococci: 15 years and counting. J Hosp Infect, 53(3), 159-71 (2003).
12. Anonymous, From the Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. Jama, 288(17), 2116 (2002).
13. Anonymous, From the Centers for Disease Control. Staphylococcus aureus resistant to vancomycin-United States, 2002. Jama, 288(7), 824-5 (2002).
14. Tenover FC, Swenson JM, O'Hara CM, Stocker SA, Ability of commercial and reference antimicrobial susceptibility testing methods to detect vancomycin resistance in enterococci. J Clin Microbiol, 33(6), 1524-7 (1995).
15. Tenover FC, Weigel LM, Appelbaum PC, et al., Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother, 48(1), 275-80 (2004).
16. Jacoby GA, Epidemiology of extended-spectrum beta-lactamases. Clin Infect Dis, 27(1), 81-3 (1998).
17. Sturenburg E, Mack D, Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect, 47(4), 273-95 (2003).
18. Jacoby GA, Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams. Infect Dis Clin North Am, 11(4), 875-87 (1997).